Detection of adalimumab and antibodies-to-adalimumab using the Anser ® ADA Homogeneous Mobility Shift Assay.

CONCLUSION: In this real-world cross-sectional population, serum ADL levels decreased with increasing ATA titers, with low ATA titers (≤7 U/mL) significantly reducing serum ADL compared to ATA-negative samples. Expression of inflammatory markers significantly increased at higher ATA titers (>7 U/mL). These findings highlight the clinical importance of monitoring patients for drug levels and anti-drug antibody titers.
PMID: 28145781 [PubMed - as supplied by publisher]

Source: Current Medical Research and Opinion - February 3, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research